<!doctype html><html lang=zh-tw><head><meta charset=utf-8><meta name=description content="Review COAGULOPATHIES :::columns
林協霆 :::split
2023-08-25 :::
     Screening Test Abnormalities in Inherited and Acquired Coagulopathies   :::columns"><meta property="og:title" content><meta property="og:description" content><meta property="og:type" content="website"><meta property="og:url" content><meta property="og:image" content="https://og-ph6wrfvo1-htlin222.vercel.app/api/blog?templateTitle="><title>蜥蜴花園🦎🌱🪴🌲</title><meta name=viewport content="width=device-width,initial-scale=1"><link rel=alternate type=application/rss+xml href=https://www.physician.tw//feed.xml title><link rel="shortcut icon" type=image/png href=https://www.physician.tw//icon.png><link href=https://www.physician.tw/styles.720e2c4835986a3891d6eef3a55faa22.min.css rel=stylesheet><link href=https://www.physician.tw/styles/_light_syntax.86a48a52faebeaaf42158b72922b1c90.min.css rel=stylesheet id=theme-link><script src=https://www.physician.tw/js/darkmode.dfadb738e747a87e78c7144d7267f1bc.min.js></script>
<script src=https://www.physician.tw/js/util.6f22941e242efae60fd84e7c32e874fa.min.js></script>
<link rel=preload href=https://cdn.jsdelivr.net/npm/katex@0.15.1/dist/katex.min.css as=style onload='this.onload=null,this.rel="stylesheet"' integrity=sha384-R4558gYOUz8mP9YWpZJjofhk+zx0AS11p36HnD2ZKj/6JR5z27gSSULCNHIRReVs crossorigin=anonymous><script defer src=https://cdn.jsdelivr.net/npm/katex@0.15.1/dist/katex.min.js integrity=sha384-z1fJDqw8ZApjGO3/unPWUPsIymfsJmyrDVWC8Tv/a1HeOtGmkwNd/7xUS0Xcnvsx crossorigin=anonymous></script>
<script defer src=https://cdn.jsdelivr.net/npm/katex@0.15.1/dist/contrib/auto-render.min.js integrity=sha384-+XBljXPPiv+OzfbB3cVmLHf4hdUFHlWNZN5spNQ7rmHTXpd7WvJum6fIACpNNfIR crossorigin=anonymous></script>
<script defer src=https://cdn.jsdelivr.net/npm/katex@0.16.2/dist/contrib/copy-tex.min.js integrity=sha384-ww/583aHhxWkz5DEVn6OKtNiIaLi2iBRNZXfJRiY1Ai7tnJ9UXpEsyvOITVpTl4A crossorigin=anonymous></script>
<script async src=https://unpkg.com/@floating-ui/core@0.7.3></script>
<script async src=https://unpkg.com/@floating-ui/dom@0.5.4></script>
<script async src=https://www.physician.tw/js/popover.f03552ccb84d99ca615d1cfb9abde59e.min.js></script>
<script defer src=https://www.physician.tw/js/code-title.ce4a43f09239a9efb48fee342e8ef2df.min.js></script>
<script defer src=https://www.physician.tw/js/clipboard.2913da76d3cb21c5deaa4bae7da38c9f.min.js></script>
<script defer src=https://www.physician.tw/js/callouts.7723cac461d613d118ee8bb8216b9838.min.js></script>
<script>const SEARCH_ENABLED=!1,LATEX_ENABLED=!0,PRODUCTION=!0,BASE_URL="https://www.physician.tw/",fetchData=Promise.all([fetch("https://www.physician.tw/indices/linkIndex.357a117d84ac53f7b6d803e28b8795df.min.json").then(e=>e.json()).then(e=>({index:e.index,links:e.links})),fetch("https://www.physician.tw/indices/contentIndex.be8b0ee8582f9c3295529c05bdd3bcd8.min.json").then(e=>e.json())]).then(([{index:e,links:t},n])=>({index:e,links:t,content:n})),render=()=>{const e=new URL(BASE_URL),t=e.pathname,n=window.location.pathname,s=t==n;addCopyButtons(),addTitleToCodeBlocks(),addCollapsibleCallouts(),initPopover("https://www.physician.tw",!0);const o=document.getElementById("footer");if(o){const e=document.getElementById("graph-container");if(!e)return requestAnimationFrame(render);e.textContent="";const t=s&&!1;drawGraph("https://www.physician.tw",t,[{"/moc":"#4388cc"}],t?{centerForce:1,depth:-1,enableDrag:!0,enableLegend:!1,enableZoom:!0,fontSize:.5,linkDistance:1,opacityScale:3,repelForce:1,scale:1.4}:{centerForce:1,depth:1,enableDrag:!0,enableLegend:!1,enableZoom:!0,fontSize:.6,linkDistance:1,opacityScale:3,repelForce:2,scale:1.2})}},init=(e=document)=>{addCopyButtons(),addTitleToCodeBlocks(),renderMathInElement(e.body,{delimiters:[{left:"$$",right:"$$",display:!0},{left:"$",right:"$",display:!1}],macros:{'’':"'"},throwOnError:!1})}</script><script type=module>
    import { attachSPARouting } from "https:\/\/www.physician.tw\/js\/router.9d4974281069e9ebb189f642ae1e3ca2.min.js"
    attachSPARouting(init, render)
  </script></head><body><div id=search-container><div id=search-space><input autocomplete=off id=search-bar name=search type=text aria-label=搜尋 placeholder="請輸入像是：hypertension 之類的來看沒有沒什麼有趣的🎳"><div id=results-container></div></div></div><script src=https://cdn.jsdelivr.net/npm/flexsearch@0.7.21/dist/flexsearch.bundle.js integrity="sha256-i3A0NZGkhsKjVMzFxv3ksk0DZh3aXqu0l49Bbh0MdjE=" crossorigin=anonymous defer></script>
<script defer src=https://www.physician.tw/js/full-text-search.e6e2e0c213187ca0c703d6e2c7a77fcd.min.js></script><div class=singlePage><header><h1 id=page-title><a href=https://www.physician.tw/>蜥蜴花園🦎🌱🪴🌲</a></h1><div class=spacer></div><div id=search-icon><p>搜尋</p><svg tabindex="0" aria-labelledby="title desc" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 19.9 19.7"><title id="title">搜尋圖示</title><desc id="desc">打開搜尋圖標</desc><g class="search-path" fill="none"><path stroke-linecap="square" d="M18.5 18.3l-5.4-5.4"/><circle cx="8" cy="8" r="7"/></g></svg></div><div class=darkmode><input class=toggle id=darkmode-toggle type=checkbox tabindex=-1>
<label id=toggle-label-light for=darkmode-toggle tabindex=-1><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" id="dayIcon" viewBox="0 0 35 35" style="enable-background:new 0 0 35 35"><title>明亮模式</title><path d="M6 17.5C6 16.672 5.328 16 4.5 16h-3C.672 16 0 16.672.0 17.5S.672 19 1.5 19h3C5.328 19 6 18.328 6 17.5zM7.5 26c-.414.0-.789.168-1.061.439l-2 2C4.168 28.711 4 29.086 4 29.5 4 30.328 4.671 31 5.5 31c.414.0.789-.168 1.06-.44l2-2C8.832 28.289 9 27.914 9 27.5 9 26.672 8.329 26 7.5 26zm10-20C18.329 6 19 5.328 19 4.5v-3C19 .672 18.329.0 17.5.0S16 .672 16 1.5v3C16 5.328 16.671 6 17.5 6zm10 3c.414.0.789-.168 1.06-.439l2-2C30.832 6.289 31 5.914 31 5.5 31 4.672 30.329 4 29.5 4c-.414.0-.789.168-1.061.44l-2 2C26.168 6.711 26 7.086 26 7.5 26 8.328 26.671 9 27.5 9zM6.439 8.561C6.711 8.832 7.086 9 7.5 9 8.328 9 9 8.328 9 7.5c0-.414-.168-.789-.439-1.061l-2-2C6.289 4.168 5.914 4 5.5 4 4.672 4 4 4.672 4 5.5c0 .414.168.789.439 1.06l2 2.001zM33.5 16h-3c-.828.0-1.5.672-1.5 1.5s.672 1.5 1.5 1.5h3c.828.0 1.5-.672 1.5-1.5S34.328 16 33.5 16zM28.561 26.439C28.289 26.168 27.914 26 27.5 26c-.828.0-1.5.672-1.5 1.5.0.414.168.789.439 1.06l2 2C28.711 30.832 29.086 31 29.5 31c.828.0 1.5-.672 1.5-1.5.0-.414-.168-.789-.439-1.061l-2-2zM17.5 29c-.829.0-1.5.672-1.5 1.5v3c0 .828.671 1.5 1.5 1.5s1.5-.672 1.5-1.5v-3C19 29.672 18.329 29 17.5 29zm0-22C11.71 7 7 11.71 7 17.5S11.71 28 17.5 28 28 23.29 28 17.5 23.29 7 17.5 7zm0 18c-4.136.0-7.5-3.364-7.5-7.5s3.364-7.5 7.5-7.5 7.5 3.364 7.5 7.5S21.636 25 17.5 25z"/></svg></label><label id=toggle-label-dark for=darkmode-toggle tabindex=-1><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" id="nightIcon" viewBox="0 0 100 100" style="enable-background='new 0 0 100 100'"><title>黑暗模式</title><path d="M96.76 66.458c-.853-.852-2.15-1.064-3.23-.534-6.063 2.991-12.858 4.571-19.655 4.571C62.022 70.495 50.88 65.88 42.5 57.5 29.043 44.043 25.658 23.536 34.076 6.47c.532-1.08.318-2.379-.534-3.23-.851-.852-2.15-1.064-3.23-.534-4.918 2.427-9.375 5.619-13.246 9.491-9.447 9.447-14.65 22.008-14.65 35.369.0 13.36 5.203 25.921 14.65 35.368s22.008 14.65 35.368 14.65c13.361.0 25.921-5.203 35.369-14.65 3.872-3.871 7.064-8.328 9.491-13.246C97.826 68.608 97.611 67.309 96.76 66.458z"/></svg></label></div></header><article><p class=meta>最後更新於
Aug 28, 2023
<a href=https://github.com/htlin222/garden/tree/hugo/content/slides/coagulopathy.md rel=noopener>🪚 編輯原始文件</a></p><ul class=tags></ul><aside class=mainTOC><details><summary>📒目錄</summary><nav id=TableOfContents><ol><li><ol><li></li></ol></li></ol><ol><li><a href=#林協霆>林協霆</a></li><li><a href=#2023-08-25>2023-08-25</a></li><li><a href=#screening-test-abnormalities-in-inherited-and-acquired-coagulopathies>Screening Test Abnormalities in Inherited and Acquired Coagulopathies</a></li><li><a href=#pt>PT</a><ol><li><a href=#prothombin-time>Prothombin Time</a></li></ol></li><li><a href=#inr>INR</a><ol><li><a href=#patients-pt-control-ptisi>(patient&rsquo;s PT/ Control PT)^ISI</a></li></ol></li><li><a href=#high-inr>High INR</a></li><li><a href=#aptt--activated-partial-thromboplastin-time>aPTT : Activated Partial Thromboplastin Time</a></li><li><a href=#fibrinogen>Fibrinogen</a><ol><li></li></ol></li><li><a href=#further-coagulation-tests>Further coagulation tests</a><ol><li><a href=#mixing-study>Mixing study</a></li><li><a href=#coagulation-factor-levels>Coagulation factor levels</a></li><li><a href=#dic-screen>DIC screen</a></li></ol></li><li><a href=#hemophilias>Hemophilias</a><ol><li><a href=#hemophilias-clinical-manifestations>Hemophilias Clinical manifestations</a></li><li><a href=#diagnosis>Diagnosis</a></li><li><a href=#prophylaxis>Prophylaxis</a></li><li><a href=#hemophilias-treatment>Hemophilias Treatment</a></li></ol></li><li><a href=#coagulation-factor-inhibitors-anti-factor-antibodies-anti-factor-viii-8-most-common>Coagulation factor inhibitors (anti-factor antibodies; anti-factor VIII 8️⃣ most common)</a><ol><li><a href=#etiologies>Etiologies</a></li><li><a href=#diagnosis-1>Diagnosis</a></li></ol></li><li><a href=#treatment>Treatment</a></li><li><a href=#disseminated-intravascular-coagulation-dic-nejm-2014370847>Disseminated intravascular coagulation (DIC) (NEJM 2014;370:847)</a><ol><li><a href=#pathogenesis>Pathogenesis</a></li></ol></li><li><a href=#pathogenesis-of-dic-in-sepsis>Pathogenesis of DIC in Sepsis</a><ol><li><a href=#diagnosis-2>Diagnosis</a></li><li><a href=#treatment-1>Treatment</a></li></ol></li><li><a href=#vitamin-k-deficiency>Vitamin K deficiency</a><ol><li><a href=#etiologies-1>Etiologies</a></li></ol></li><li><a href=#andexanet-alfa-factor-xa-decoy-receptor>Andexanet alfa (factor Xa decoy receptor)</a></li></ol></nav></details></aside><a href=#review><h4 id=review><span class=hanchor arialabel=Anchor># </span>Review</h4></a><a href=#coagulopathies><h1 id=coagulopathies><span class=hanchor arialabel=Anchor># </span>COAGULOPATHIES</h1></a><p>:::columns</p><a href=#林協霆><h2 id=林協霆><span class=hanchor arialabel=Anchor># </span>林協霆</h2></a><p>:::split</p><a href=#2023-08-25><h2 id=2023-08-25><span class=hanchor arialabel=Anchor># </span>2023-08-25</h2></a><p>:::</p><hr><p><img src=https://i.imgur.com/vjuYH8L.png width=auto alt=h:650></p><hr><p><img src=https://i.imgur.com/RG3EW7j.png width=auto alt=h:650></p><hr><a href=#screening-test-abnormalities-in-inherited-and-acquired-coagulopathies><h2 id=screening-test-abnormalities-in-inherited-and-acquired-coagulopathies><span class=hanchor arialabel=Anchor># </span>Screening Test Abnormalities in Inherited and Acquired Coagulopathies</h2></a><p><img src=https://i.imgur.com/Pl2E669.png width=auto alt=h:200></p><hr><p>:::columns</p><a href=#pt><h2 id=pt><span class=hanchor arialabel=Anchor># </span>PT</h2></a><hr><a href=#prothombin-time><h3 id=prothombin-time><span class=hanchor arialabel=Anchor># </span>Prothombin Time</h3></a><ul><li>normal ~11-14 seconds,</li><li>for variation, a derived value was created called the international normalized ratio (INR).</li></ul><p>:::split</p><a href=#inr><h2 id=inr><span class=hanchor arialabel=Anchor># </span>INR</h2></a><hr><a href=#patients-pt-control-ptisi><h3 id=patients-pt-control-ptisi><span class=hanchor arialabel=Anchor># </span>(patient&rsquo;s PT/ Control PT)^ISI</h3></a><p>ISI= International Sensitivity Index (specific for each lot of reagent)</p><p>:::</p><hr><a href=#high-inr><h2 id=high-inr><span class=hanchor arialabel=Anchor># </span>High INR</h2></a><div class=highlight><div class=chroma><table class=lntable><tr><td class=lntd><pre tabindex=0 class=chroma><code><span class=lnt>1
</span></code></pre></td><td class=lntd><pre tabindex=0 class=chroma><code class=language-python data-lang=python><span class=line><span class=cl><span class=nb>print</span><span class=p>(</span><span class=s2>&#34;hellow&#34;</span><span class=p>)</span>
</span></span></code></pre></td></tr></table></div></div><blockquote><p>Vitamin K deficiency (e.g. malnutrition, malabsorption, antibiotics)
Increased consumption of clotting factors
Sepsis/ DIC</p></blockquote><hr><a href=#aptt--activated-partial-thromboplastin-time><h2 id=aptt--activated-partial-thromboplastin-time><span class=hanchor arialabel=Anchor># </span>aPTT : Activated Partial Thromboplastin Time</h2></a><ul><li>normal range for aPTT is ~25-40 seconds,</li><li>Unlike PT and the INR, there is no equivalent standardization of the aPTT.</li></ul><div class=highlight><div class=chroma><table class=lntable><tr><td class=lntd><pre tabindex=0 class=chroma><code><span class=lnt>1
</span><span class=lnt>2
</span><span class=lnt>3
</span><span class=lnt>4
</span></code></pre></td><td class=lntd><pre tabindex=0 class=chroma><code class=language-fallback data-lang=fallback><span class=line><span class=cl>Some anticoagulants
</span></span><span class=line><span class=cl>Von Willebrand disease
</span></span><span class=line><span class=cl>Hemophilia
</span></span><span class=line><span class=cl>Antiphospholipid antibodies Sepsis / DIC
</span></span></code></pre></td></tr></table></div></div><hr><a href=#fibrinogen><h2 id=fibrinogen><span class=hanchor arialabel=Anchor># </span>Fibrinogen</h2></a><ul><li>formation of the platelet plug</li><li>precursor for fibrin, the penultimate step of the whole coagulation cascade.</li><li>Synthesized in the liver.</li><li>200-400 mg/dL.</li></ul><a href=#high-fibrinogen><h4 id=high-fibrinogen><span class=hanchor arialabel=Anchor># </span>High Fibrinogen</h4></a><p>Acute phase reactant</p><a href=#low-fibrinogen><h4 id=low-fibrinogen><span class=hanchor arialabel=Anchor># </span>Low Fibrinogen</h4></a><p>Liver failure
DIC</p><hr><a href=#further-coagulation-tests><h2 id=further-coagulation-tests><span class=hanchor arialabel=Anchor># </span>Further coagulation tests</h2></a><hr><a href=#mixing-study><h3 id=mixing-study><span class=hanchor arialabel=Anchor># </span>Mixing study</h3></a><ul><li>useful if ⬆️ PT or PTT</li><li>mix Pt’s plasma 1:1 with normal plasma</li><li>and retest<ul><li>PT/PTT normalizes<ul><li>👉 factor deficiency</li></ul></li><li>PT/PTT remains elevated<ul><li>👉 factor inhibitor</li></ul></li></ul></li></ul><hr><a href=#coagulation-factor-levels><h3 id=coagulation-factor-levels><span class=hanchor arialabel=Anchor># </span>Coagulation factor levels</h3></a><p>useful if mixing study suggests factor deficiency</p><ul><li>DIC<ul><li>👉 all factors consumed<ul><li>所以 👉 ⬇️ factors V and VIII 8️⃣</li></ul></li></ul></li><li>Liver disease<ul><li>👉 ⬇️ all factors except VIII 8️⃣;<ul><li>所以 👉 ⬇️ factor V, normal factor VIII 8️⃣</li></ul></li></ul></li><li>Vitamin K deficiency<ul><li>👉 ⬇️ factors II, VII, IX 9️⃣, X 🔟 (and protein C, S)<ul><li>所以 👉 normal V and VIII 8️⃣</li></ul></li></ul></li></ul><hr><a href=#dic-screen><h3 id=dic-screen><span class=hanchor arialabel=Anchor># </span>DIC screen</h3></a><ul><li>⬇️ fibrinogen (consumed)</li><li>fibrin degradation products<ul><li>(FDPs, ⊕ from intense fibrinolysis),</li></ul></li><li>⬆️ D-dimer<ul><li>more specific FDP test that detects degradation of X 🔟-linked fibrin</li></ul></li></ul><blockquote><p>JAMA 2016;316:2146</p></blockquote><hr><a href=#hemophilias><h2 id=hemophilias><span class=hanchor arialabel=Anchor># </span>Hemophilias</h2></a><ul><li><code>X-linked</code> recessive factor VIII 8️⃣ (hemophilia A) or factor IX 9️⃣ (hemophilia B) deficiency</li><li>Classification:<ul><li>mild (5–25% normal factor activity)</li><li>moderate (1–5%)</li><li>severe (&lt;1%)</li></ul></li></ul><blockquote><p>(Lancet 2016;388:187)</p></blockquote><hr><a href=#hemophilias-clinical-manifestations><h3 id=hemophilias-clinical-manifestations><span class=hanchor arialabel=Anchor># </span>Hemophilias Clinical manifestations</h3></a><ul><li>hematomas, hemarthroses, bruising, bleeding (mucosal, GI, GU)</li></ul><a href=#diagnosis><h3 id=diagnosis><span class=hanchor arialabel=Anchor># </span>Diagnosis</h3></a><ul><li>⬆️ PTT (normalizes w/mixing study),</li><li>normal PT & vWF,</li><li>⬇️ factor VIII 8️⃣ or IX 9️⃣</li></ul><a href=#prophylaxis><h3 id=prophylaxis><span class=hanchor arialabel=Anchor># </span>Prophylaxis</h3></a><ul><li>indicated if &lt;1% activity of factor VIII 8️⃣ or IX 9️⃣</li></ul><hr><a href=#hemophilias-treatment><h3 id=hemophilias-treatment><span class=hanchor arialabel=Anchor># </span>Hemophilias Treatment</h3></a><ul><li>purified/recomb. factor VIII 8️⃣ or IX 9️⃣;</li><li>desmopressin (mild disease)</li><li>anti-fibrinolytics<ul><li>aminocaproic acid</li><li>tranexamic acid</li></ul></li><li>cryo (FVIII 8️⃣);</li><li>emicizumab (bridges factor IX 9️⃣ and X 🔟), effective for hemophilia A with and w/o inhibitors</li></ul><blockquote><p>(NEJM 2017;377:809 & 2018;379:811)</p></blockquote><hr><a href=#coagulation-factor-inhibitors-anti-factor-antibodies-anti-factor-viii-8-most-common><h2 id=coagulation-factor-inhibitors-anti-factor-antibodies-anti-factor-viii-8-most-common><span class=hanchor arialabel=Anchor># </span>Coagulation factor inhibitors (anti-factor antibodies; anti-factor VIII 8️⃣ most common)</h2></a><a href=#etiologies><h3 id=etiologies><span class=hanchor arialabel=Anchor># </span>Etiologies</h3></a><ul><li>hemophilia; postpartum;</li><li>lymphoproliferative & autoimmune disorders;</li><li>cancers</li></ul><a href=#diagnosis-1><h3 id=diagnosis-1><span class=hanchor arialabel=Anchor># </span>Diagnosis</h3></a><ul><li>⬆️ PTT (does not normalize with mixing study);</li><li>Bethesda assay quantitates titer</li></ul><hr><a href=#treatment><h2 id=treatment><span class=hanchor arialabel=Anchor># </span>Treatment</h2></a><ul><li>if high titer 👉 recomb. factor VIIa, porcine factor concentrates, activated prothrombin complex;</li><li>for others 👉 high-purity human factor, plasmapheresis, immunosuppression</li></ul><hr><a href=#disseminated-intravascular-coagulation-dic-nejm-2014370847><h2 id=disseminated-intravascular-coagulation-dic-nejm-2014370847><span class=hanchor arialabel=Anchor># </span>Disseminated intravascular coagulation (DIC) (NEJM 2014;370:847)</h2></a><ul><li>Etiologies: trauma, shock, infection, malignancy (esp. APL), obstetric complications</li></ul><hr><hr><a href=#pathogenesis><h3 id=pathogenesis><span class=hanchor arialabel=Anchor># </span>Pathogenesis</h3></a><ul><li>massive activation of coagulation that overwhelms control mechanisms</li><li>Thrombosis in microvasculature 👉 ischemia + microangiopathic hemolytic anemia</li><li>Acute consumption of coagulation factors and platelets 👉 bleeding</li><li>Chronic DIC 👉 able to compensate by ⬆️ factors and platelets 👉 thrombosis</li></ul><hr><a href=#pathogenesis-of-dic-in-sepsis><h2 id=pathogenesis-of-dic-in-sepsis><span class=hanchor arialabel=Anchor># </span>Pathogenesis of DIC in Sepsis</h2></a><p><img src=https://i.imgur.com/1kWKoJb.jpg width=auto alt=" h:600"></p><hr><a href=#diagnosis-2><h3 id=diagnosis-2><span class=hanchor arialabel=Anchor># </span>Diagnosis</h3></a><ul><li>⬆️ PT, ⬆️ PTT,</li><li>⬇️ fibrinogen (may be nl b/c acute phase),</li><li>⊕ FDP/D-dimer,</li><li>⬇️ plts,</li><li>⊕ schistos,</li><li>⬆️ LDH,</li><li>⬇️ hapto;</li><li>chronic DIC:<ul><li>⊕ FDP/D-dimer,</li><li>variable plts,</li><li>other labs nl</li></ul></li></ul><hr><a href=#treatment-1><h3 id=treatment-1><span class=hanchor arialabel=Anchor># </span>Treatment</h3></a><ul><li>Treatment underlying process;</li><li>support with FFP, cryo (goal fbgn >100 mg/dL) & plts</li></ul><hr><a href=#vitamin-k-deficiency><h2 id=vitamin-k-deficiency><span class=hanchor arialabel=Anchor># </span>Vitamin K deficiency</h2></a><a href=#etiologies-1><h3 id=etiologies-1><span class=hanchor arialabel=Anchor># </span>Etiologies</h3></a><ul><li>malnutrition,</li><li>⬇️ absorption (antibiotic suppression of vitamin K-producing intestinal flora or malabsorption)</li><li>liver disease (⬇️ stores)</li><li>warfarin</li></ul><hr><p>Properties and Antidotes for Anticoagulants & Fibrinolytics</p><table><thead><tr><th>Anticoag.</th><th>t1/2</th><th>Labs</th><th>Rx for O/D w/ Serious Bleeding (+ d/c anticoag)</th></tr></thead><tbody><tr><td>UFH</td><td>60–90′</td><td>↑ PTT</td><td>Protamine IV 1 mg/100 U UFH (max 50 mg). For infusions, dose to reverse 2× UFH given per h.</td></tr><tr><td>LMWH</td><td>2–7°</td><td>anti-Xa*</td><td>Protamine reverses ~60%. 1 mg per 1 mg enox.</td></tr><tr><td>Bivalirudin</td><td>25′</td><td>↑ PTT</td><td>Dialysis</td></tr><tr><td>Argatroban</td><td>45′</td><td>↑ PTT</td><td>? Dialysis</td></tr><tr><td>Warfarin</td><td>36°</td><td>↑ PT</td><td><code>No bleeding</code>: vit K 2.5 mg PO if INR >9, o/w no e/o clinical benefit (Blood Adv 2019;3:789)</td></tr><tr><td></td><td></td><td></td><td><code>Bleeding</code>: vit. K 10 mg IV + either 4F-PCC (KCentra, 25, 35, or 50 U/kg for INR 2–4, 4–6, or >6) or FFP 2–4 U IV q6–8h (slower, more volume)</td></tr></tbody></table><hr><p>Properties and Antidotes for Anticoagulants & Fibrinolytics</p><table><thead><tr><th>Fibrinolytic</th><th>t1/2</th><th>Labs</th><th>Rx for O/D w/ Serious Bleeding (+ d/c anticoag)</th></tr></thead><tbody><tr><td>Fibrinolytic</td><td>20′, LK</td><td>↓ fbgn</td><td>Cryo, FFP, ± tranexamic or aminocaproic acid</td></tr><tr><td>Rivaroxaban<br>Apixaban<br>Dabigatran</td><td>8–12°<br>K > L</td><td>↑ PT*<br>anti-Xa*</td><td><code>Andexanet alfa</code></td></tr><tr><td>Dabigatran</td><td>~12°</td><td>K</td><td>↑ PTT* Idarucizumab: mAb binds drug (NEJM 2017;377:431)</td></tr></tbody></table><pre><code>* Routine monitoring not performed.
* Mode of excretion:
    * K, kidney
    * L, liver
    * RES, reticuloendothelial system
</code></pre><hr><a href=#andexanet-alfa-factor-xa-decoy-receptor><h2 id=andexanet-alfa-factor-xa-decoy-receptor><span class=hanchor arialabel=Anchor># </span>Andexanet alfa (factor Xa decoy receptor)</h2></a><p>reverse apixaban and rivaroxaban in patients with life-threatening or uncontrolled bleeding</p><ul><li>800 mg bolus (30 mg/min)</li><li>→ 8 mg/min infusion<ul><li>(½ of above if taking ½ dose DOAC or ≥8 hrs since last dose; NEJM 2019;380:1326);</li></ul></li><li>4F-PCC: prothrombin complex concentrate (FII, VII, IX, X; Protein C & S). if andexanet not available</li></ul></article><hr><div class=page-end id=footer><div class=backlinks-container><h3>↩️ 反向連結</h3><ul class=backlinks><li>🤭沒有找到反向連結</li></ul></div><div><script async src=https://cdn.jsdelivr.net/npm/d3@6.7.0/dist/d3.min.js integrity="sha256-+7jaYCp29O1JusNWHaYtgUn6EhuP0VaFuswhNV06MyI=" crossorigin=anonymous></script><h3>🤯互動圖</h3><div id=graph-container></div><style>:root{--g-node:var(--secondary);--g-node-active:var(--primary);--g-node-inactive:var(--visited);--g-link:var(--outlinegray);--g-link-active:#5a7282}</style><script src=https://www.physician.tw/js/graph.2d9e48dbe7ea47c0ef1c58296ce14448.js></script></div></div><div><div id=disqus_thread></div><script type=application/javascript>window.disqus_config=function(){},function(){if(["localhost","127.0.0.1"].indexOf(window.location.hostname)!=-1){document.getElementById("disqus_thread").innerHTML="Disqus comments not available by default when the website is previewed locally.";return}var t=document,e=t.createElement("script");e.async=!0,e.src="//physician.disqus.com/embed.js",e.setAttribute("data-timestamp",+new Date),(t.head||t.body).appendChild(e)}()</script><noscript>Please enable JavaScript to view the <a href=https://disqus.com/?ref_noscript>comments powered by Disqus.</a></noscript><a href=https://disqus.com class=dsq-brlink>comments powered by <span class=logo-disqus>Disqus</span></a></div><div id=contact_buttons><footer><p>本網站是由 Hsieh-Ting Lin 以❤️ 用 <a href=https://github.com/jackyzha0/quartz>Quartz</a>這個酷東西種出來🪴 , © 2023</p><p><a href=https://www.buymeacoffee.com/htl.lizard><img src=https://cdn.buymeacoffee.com/buttons/v2/default-yellow.png width=200></a></p><ul><li><a href=https://www.physician.tw/>🏠首頁</a></li><li><a href=https://www.facebook.com/Tim.H.Lin>Facebook</a></li><li><a href=https://twitter.com/htlin222>Twitter</a></li><li><a href=https://github.com/htlin222>GitHub</a></li><li><a href=https://htlin.site>Blog</a></li><li><a href=https://medium.com/@hsieh-ting-lin>Medium</a></li></ul></footer></div></div></body></html>